Clinical Trial Update: A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

A Phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors was terminated. The sponsor was Novartis Pharmaceuticals, and the trial included pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma
• Glioblastoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• [177Lu]Lu-FF58

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 1 | Status: TERMINATED